Celgene: Headwinds For Otezla Could Weigh
January 26, 2018 at 15:14 PM EST
CELG beat Q4 revenue expectations on 20% price hikes for Revlimid. Once price hikes run their course CELG could face headwinds for Otezla. In the near term, it could be difficult to justify CELG's trading multiple which exceeds 16x run-rate EBITDA.
